Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial UpdatesGuruFocus · 3 days ago
Stoke Therapeutics: The Market Misread A Key FDA WinSeeking Alpha · 6 days ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire · Oct 16, 2026
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingBusiness Wire · Oct 12, 2026
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual MeetingBusiness Wire · Oct 6, 2026
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeGuruFocus · Oct 5, 2026Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$0.80 | -$0.93 | Miss |
| May 7, 2026 | -$0.80 | -$0.79 | Beat |
| Mar 16, 2026 | -$0.75 | -$0.97 | Miss |
| Nov 4, 2025 | -$0.54 | -$0.65 | Miss |
| Aug 12, 2025 | -$0.57 | -$0.40 | Beat |
| May 13, 2025 | -$0.37 | $1.90 | Beat |